Gunderson Dettmer Represents Guardant Health in $550 Million Convertible Senior Notes Offering
Gunderson Dettmer represented Guardant Health, a precision oncology company listed on Nasdaq under the symbol “GH,” in its offering of $550 million aggregate principal amount of 0% convertible senior notes due 2032, which includes the exercise in full of the initial purchasers’ option to purchase up to an additional $50 million principal amount of notes.
Guardant Health used approximately $501.7 million of the net proceeds to repurchase for cash approximately $395.2 million aggregate principal amount of its 0% convertible senior notes due 2027 in note repurchase transactions. The company used the remaining net proceeds, plus cash on hand, to fund the $51.7 million cost of entering into capped call transactions.
The Gunderson deal team was led by Andrew Thorpe and Elena Vespoli and included Daniel Reichert, Lydia Wang, Jaime Narayan, and Morgan Otway.
